These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11470602)

  • 1. Screening of drug candidates for their drug--drug interaction potential.
    Rodrigues AD; Lin JH
    Curr Opin Chem Biol; 2001 Aug; 5(4):396-401. PubMed ID: 11470602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery.
    Yan Z; Caldwell GW
    Curr Top Med Chem; 2001 Nov; 1(5):403-25. PubMed ID: 11899105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of CYP-mediated drug interactions in vivo using in vitro data.
    Foti RS; Wahlstrom JL
    IDrugs; 2008 Dec; 11(12):900-5. PubMed ID: 19051152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition and induction of cytochrome P450 and the clinical implications.
    Lin JH; Lu AY
    Clin Pharmacokinet; 1998 Nov; 35(5):361-90. PubMed ID: 9839089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50).
    Gao F; Johnson DL; Ekins S; Janiszewski J; Kelly KG; Meyer RD; West M
    J Biomol Screen; 2002 Aug; 7(4):373-82. PubMed ID: 12230892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental models for evaluating enzyme induction potential of new drug candidates in animals and humans and a strategy for their use.
    Thompson TN
    Adv Pharmacol; 1997; 43():205-29. PubMed ID: 9342178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies.
    Prueksaritanont T; Kuo Y; Tang C; Li C; Qiu Y; Lu B; Strong-Basalyga K; Richards K; Carr B; Lin JH
    Drug Metab Dispos; 2006 Sep; 34(9):1546-55. PubMed ID: 16782766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of cytochrome P450 drug interaction screening in drug discovery.
    Foti RS; Wienkers LC; Wahlstrom JL
    Comb Chem High Throughput Screen; 2010 Feb; 13(2):145-58. PubMed ID: 20053168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro cytochrome P450 inhibition and induction.
    Walsky RL; Boldt SE
    Curr Drug Metab; 2008 Nov; 9(9):928-39. PubMed ID: 18991590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of cytochrome P450 enzymes: a view on human in vivo findings.
    Hukkanen J
    Expert Rev Clin Pharmacol; 2012 Sep; 5(5):569-85. PubMed ID: 23121279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Problems associated with in vitro assessment of drug inhibition of CYP3A4 and other P-450 enzymes and its impact on drug discovery.
    Wienkers LC
    J Pharmacol Toxicol Methods; 2001; 45(1):79-84. PubMed ID: 11489668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction.
    Li AP; Maurel P; Gomez-Lechon MJ; Cheng LC; Jurima-Romet M
    Chem Biol Interact; 1997 Nov; 107(1-2):5-16. PubMed ID: 9402946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective.
    Chu V; Einolf HJ; Evers R; Kumar G; Moore D; Ripp S; Silva J; Sinha V; Sinz M; Skerjanec A
    Drug Metab Dispos; 2009 Jul; 37(7):1339-54. PubMed ID: 19389860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure in drug development: the role of inhibition and induction of cytochrome P450 enzymes.
    Hengstler JG; Bolt HM
    Arch Toxicol; 2008 Oct; 82(10):665-6. PubMed ID: 18751968
    [No Abstract]   [Full Text] [Related]  

  • 15. In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies.
    Li Y; Zhou D; Ferguson SS; Dorff P; Simpson TR; Grimm SW
    Xenobiotica; 2010 Nov; 40(11):721-9. PubMed ID: 20937004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of higher-throughput high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry assays to conduct cytochrome P450s CYP2D6 and CYP3A4 enzyme inhibition studies in human liver microsomes.
    Chu I; Favreau L; Soares T; Lin Cc; Nomeir AA
    Rapid Commun Mass Spectrom; 2000; 14(4):207-14. PubMed ID: 10669878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A sensitive and high-throughput LC-MS/MS method for inhibition assay of seven major cytochrome P450s in human liver microsomes using an in vitro cocktail of probe substrates.
    Liu LY; Han YL; Zhu JH; Yu Q; Yang QJ; Lu J; Guo C
    Biomed Chromatogr; 2015 Mar; 29(3):437-44. PubMed ID: 25098274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions.
    Crespi CL; Penman BW
    Adv Pharmacol; 1997; 43():171-88. PubMed ID: 9342176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary hepatocyte cultures as an in vitro experimental model for the evaluation of pharmacokinetic drug-drug interactions.
    Li AP
    Adv Pharmacol; 1997; 43():103-30. PubMed ID: 9342174
    [No Abstract]   [Full Text] [Related]  

  • 20. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
    Brown HS; Galetin A; Hallifax D; Houston JB
    Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.